Date: 2015-03-23
Type of information: Licensing agreement
Compound: Antibody drug conjugate (ADC) technology
Company: Immunogen (USA - MA) Millennium Pharmaceuticals (USA - MA) Takeda Pharmaceutical (Japan)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: licensing
Action mechanism: antibody drug conjugate (ADC). An ADC consists of a monoclonal antibody that binds to a target found on cancer cells with a cancer-cell killing agent, or \"payload,\" attached. The antibody serves to target the payload specifically to the cancer cells and the payload serves to kill these cells. In some cases, the antibody also has meaningful anticancer activity.
Disease:
Details: * On March 23, 2015, Takeda Pharmaceutical Company and ImmunoGen, a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology, announced that Takeda has licensed exclusive rights to use ImmunoGen\'s ADC technology - including ImmunoGen\'s new DNA-acting IGN payload agents - to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. The agreement also provides Takeda with the option to take a license for a third target for an additional upfront fee. Takeda signed an agreement with ImmunoGen through its wholly owned subsidiary, Millennium Pharmaceuticals.
Financial terms: ImmunoGen will receive $20 million upfront and - for each target - is eligible to receive milestone payments potentially totaling up to $210 million plus royalties on the commercial net sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any ADC products resulting from this agreement.
Latest news:
